Duodart, a prostate hypertrophy compound, has settled in general hospitals. According to related industries, GSK Korea's Duodart recently passed DC of Big 5 General Hospitals such as Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital. This drug has been applied to insurance benefits since March. Duodart's benefit target is ▲ an International Prostate Symptom Score (IPSS) of 8 or more when administered to positive prostate hypertrophy, ▲ when the size of the prostate is 30ml or higher, the occupational balance test shows moderate or higher benign prostatic hypertrophy, or the Prostate specific antigen (PSA) level meets two conditions: 1.4ng/ml or higher.